Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P980052/S016

TMJ Concepts Patient Fitted Temporomandibular Joint (TMJ) Reconstruction Prosthesis System

Stryker Leibinger GmbH & Co. KG · Decision date Jul 23, 2025

FDA DECISIONP980052/S016

What did the FDA approve?

FDA records P980052/S016 as a supplement to PMA P980052, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Jul 23, 2025.

FDA approval order statement

to modify the method of inspection of the articular surface of the Fossa component to utilize the MarSurf CM Explorer Microscope
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Dental
Decision date
Jul 23, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P980052/S016
Regulatory pathway
PMA supplement
Product code
LZD
Decision code
APPR
Decision date
Jul 23, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Joint, temporomandibular, implant.

Product code
LZD
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P980052/S016 received

    Application receipt date recorded by FDA.

  2. P980052/S016 · FDA decision

    Special (Immediate Track)

  3. P980052/S017 · Related supplement

    TMJ Concepts Patient-Fitted TMJ Reconstruction Prosthesis

Timeline entries are records held by MedtechLedger for P980052. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P980052

Product / regulatory recordCompanyPathwayDecision dateSource
Stryker Leibinger GmbH & Co. KGPMA supplementMar 6, 2026FDA

Explore the linked device profile

Other records with product code LZD

Product / regulatory recordCompanyPathwayDecision dateSource
BIOMET MICROFIXATION, INCPMA supplementFeb 19, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Stryker Leibinger GmbH & Co. KG

Headquarters
Not reported
Brand website
stryker.com
FDA applicant address
Boetzinger Strasse 41, D-7911, Freiburg, D-7911

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records